Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.57 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | CCKAR | P32238 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509946 | 0.99 | KLK7 (0.58) | KLK7TACR1CTSLCTSSCTSK | |
| Bromide SCHEMBL8509179 | 0.86 | CTSS (0.44) | KLK7CTSLCTSSCTSKACE | |
| Bromide SCHEMBL8509184 | 0.86 | CTSS (0.44) | KLK7CTSLCTSSCTSKACE | |
| SCHEMBL9289986 | 0.85 | CTSS (0.45) | KLK7CTSLCTSSCTSKACE | |
| Bromide SCHEMBL8509792 | 0.83 | CTSS (0.44) | KLK7CTSLCTSSCTSKACE | |
| Bromide SCHEMBL8509794 | 0.83 | CTSS (0.44) | KLK7CTSLCTSSCTSKACE | |
| SCHEMBL8509388 | 0.82 | CTSS (0.45) | KLK7CTSLCTSSCTSKACE | |
| SCHEMBL8509384 | 0.82 | CTSS (0.45) | KLK7CTSLCTSSCTSKACE | |
| SCHEMBL8509367 | 0.81 | KLK7 (0.63) | KLK7TACR1CTSLCTSSCTSK | |
| SCHEMBL8509371 | 0.81 | KLK7 (0.63) | KLK7TACR1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643295-B1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMA SPA (IT) | 2016-04-13 | — | — | EP | disclosed |
| US-8772314-B2 | Glycine derivatives and medicinal compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-07-08 | — | — | US | disclosed |
| EP-2643295-A1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | Chiesi Farmaceutici S.p.A. (IT) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012069275-A1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | WO | disclosed |
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHRM3, GLRB, CHRNG | KLK7 2641/4885TACR1 115/4885CTSL 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.